Background: There are no studies examining the use of monoclonal antibodies in hospitalized coronavirus disease 2019 (COVID-19) patients within the Indian population.
Objectives: To determine the efficacy of monoclonal antibodies in hospitalized COVID-19 patients.
Materials And Methods: This retrospective cohort observational study was conducted from June 2021 to March 2022 in the Department of Critical Care Medicine at a tertiary care hospital in Pune, Maharashtra, India. The study included two cohorts of COVID-19 patients-a study group that received casirivimab/imdevimab infusion and a control group that did not receive monoclonal antibodies. The primary outcome measure was the assessment of the saturation of peripheral oxygen (SpO) to the fraction of inspired oxygen (FiO) ratio. Secondary outcome measures included the need for the intensive care unit (ICU) admission and mechanical ventilation, duration of hospital stay, and inhospital mortality.
Results: The mean SpO on admission and discharge, as well as the mean SpO/FiO ratio, were comparable between the two groups. No significant differences were found in the requirements for oxygen therapy, high-flow nasal cannula (HFNC), noninvasive ventilation (NIV), invasive ventilation, ICU admission, registered respiratory therapist (RRT) needs, or mortality rates between the two groups. Additionally, the median duration of hospital and ICU stay did not differ significantly between the groups.
Conclusion: Casirivimab/imdevimab therapy did not show a beneficial effect on the outcomes of hospitalized COVID-19 patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.59556/japi.72.0646 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the Pathophysiology, Diagnosis, and Treatment Options of Multiple Sclerosis.
J Integr Neurosci
January 2025
Department of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy.
The complicated neurological syndrome known as multiple sclerosis (MS) is typified by demyelination, inflammation, and neurodegeneration in the central nervous system (CNS). Managing this crippling illness requires an understanding of the complex interactions between neurophysiological systems, diagnostic techniques, and therapeutic methods. A complex series of processes, including immunological dysregulation, inflammation, and neurodegeneration, are involved in the pathogenesis of MS.
View Article and Find Full Text PDFMonitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma.
Pharmaceutics
January 2025
Laboratory Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
Multiple Myeloma (MM) is a hematologic malignancy caused by clonally expanded plasma cells that produce a monoclonal immunoglobulin (M-protein), a personalized biomarker. Recently, we developed an ultra-sensitive mass spectrometry method to quantify minimal residual disease (MS-MRD) by targeting unique M-protein peptides. Therapeutic antibodies (t-Abs), key in MM treatment, often lead to deep and long-lasting responses.
View Article and Find Full Text PDFEvolution of Alzheimer's Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy.
Pharmaceutics
January 2025
Laboratorio Experimental de Enfermedades Neurodegenerativas, Instituto Nacional de Neurología y Neurocirugía, Manuel Velasco Suárez, Mexico City 14269, Mexico.
Alzheimer's disease (AD) represents an escalating global health crisis, constituting the leading cause of dementia among the elderly and profoundly impairing their quality of life. Current FDA-approved drugs, such as rivastigmine, donepezil, galantamine, and memantine, offer only modest symptomatic relief and are frequently associated with significant adverse effects. Faced with this challenge and in line with advances in the understanding of the pathophysiology of this neurodegenerative condition, various innovative therapeutic strategies have been explored.
View Article and Find Full Text PDFIntegrating Analytical Procedures in Routine Practices of Centralized Antiblastic Compounding Units for Valorization of Residual Compounded Drugs.
Pharmaceutics
January 2025
Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.
Background/objectives: Although extemporaneous formulations of anticancer drug products for personalized therapy are produced according to Good Hospital Pharmacy Manufacturing Practice, the lack of knowledge about drug stability under clinical conditions limits the second-time use of these highly costly medications in clinical practice. Therefore, the residual compounded drugs are considered waste and a cost item that negatively affects the healthcare system. In the context of the ever-increasing interest of the health system in applying practices in line with personalized medicine and spending review policies, this research aimed to demonstrate the feasibility of incorporating analytical techniques into daily routine practice.
View Article and Find Full Text PDFThe Promising Effect of Tocilizumab on Chronic Antibody-Mediated Rejection (cAMR) of Kidney Transplant.
Pharmaceutics
January 2025
Department of General and Transplant Surgery, Poznan University of Medical Sciences, 60-355 Poznan, Poland.
: Chronic antibody-mediated rejection (cAMR) constitutes a serious challenge in the long-term success of organ transplantation. It is associated with donor-specific antibodies (DSAs) which activate a complement pathway in response to the presence of human leukocyte antigens (HLAs) on the graft, which results in chronic inflammation and leads to graft dysfunction. One of the recent promising methods of cAMR treatment is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody referred to as Tocilizumab (TCZ).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!